Genetic variation in the ATP-binding Cassette Transporter gene ABCG2 ( BCRP) in a Swedish population

• Published in: European journal of pharmaceutical sciences 2003-04, Vol.18 (5), p.359-364
• Main Authors: Bäckström, Gunilla, Taipalensuu, Jan, Melhus, Håkan, Brändström, Helena, Svensson, Ann-Cathrin, Artursson, Per, Kindmark, Andreas
• Format: Article
• Language: English
• Subjects: ABCG2; ATP Binding Cassette Transporter, Sub-Family G, Member 2; ATP-binding cassette transporter; ATP-Binding Cassette Transporters - genetics; Base Sequence; BCRP; Biological and medical sciences; Chromatography, High Pressure Liquid; Gene Frequency; General pharmacology; Genetic Variation; Genotype; Humans; Medical sciences; MEDICIN; MEDICINE; Molecular Sequence Data; Neoplasm Proteins - genetics; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Polymerase Chain Reaction; Polymorphism, Genetic; SNP; Sweden; Swedish population
• ISSN: 0928-0987; 1879-0720; 1879-0720
• DOI: 10.1016/S0928-0987(03)00038-1

The ATP-binding cassette transporter ABCG2 (also named breast cancer resistance protein, BCRP) functions as a drug efflux transporter and is expressed at high levels in the human small intestine. The aim of this study was to screen the human ABCG2 gene for genetic variation. The regions of the gene most likely to affect function, namely the coding parts, exon/intron boundaries, 5′ untranslated region and 3′ untranslated region and the proposed promoter region, were included in the screening. DNA was obtained from 60 Swedish individuals. The screening was performed using a polymerase chain reaction-denaturing high-performance liquid chromatography approach followed by sequence analysis. Eight sites of genetic variation were identified. The sequence variations considered to be most likely to affect transcription level or transport function were a CTCA deletion in the 5′ flanking region, a single nucleotide polymorphism (SNP) in a 5′ flanking CpG island, two non-synonymous SNPs, changing valine at amino acid position 12 to methionine and glutamine at position 141 to lysine, respectively. Genotyping of these sequence variations revealed linkage between the CTCA deletion and the SNP changing glutamine 141 for lysine. This information forms the basis for future association studies to investigate the genetic basis of differences of drug disposition due to sequence variation in the ABCG2 gene.